A team of colleagues at Fox Chase Cancer Center recently published an updated review of guidelines governing the use of neoadjuvant and adjuvant therapy for patients with melanoma.
Rene Y. McNall-Knapp, MD, discusses HRQOL outcomes from the ReNeu trial investigating mirdametinib in patients with NF1-PN.
IASLC presents a one-hour, live session focused on key highlights from the 2024 Hot Topic in Basic & Translational Science Conference. This webinar will…
SSO sponsors educational videoconferences for CGSO Fellows, Residents, and faculty. This session will discuss the management of melanoma in both the localized and metastatic setting.…
PHILADELPHIA (January 31, 2025) — Lilian J. Shin-Cho, PhD, an Assistant Professor in the Cancer Prevention and Control Research Program at Fox Chase Cancer Center,…
Panelists discuss how cytoreductive therapy fits into the treatment paradigm for polycythemia vera (PV), highlighting key findings from the CYTO-PV study and its subanalysis, which…
It’s difficult to imagine starting a cancer treatment path for a patient without first reviewing their molecular test results. This means getting the comprehensive story…
On February 11, 2025, the Food and Drug Administration approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients 2 years…
A full day of programming is dedicated to the tailored treatments that are required to care for this uniquely vulnerable patient population, explains Michael Verneris,…
Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to work against tumors, according to a study published in Science Advances.
